Abstract
Levels of melatonin in mammalian circulation are well documented; however, its levels in tissues and other body fluids are yet only poorly established. It is obvious that melatonin concentrations in cerebrospinal fluid (CSF) of mammals including humans are substantially higher than those in the peripheral circulation. Evidence indicates that melatonin produced in pineal gland is directly released into third ventricle via the pineal recess. In addition, brain tissue is equipped with the synthetic machinery for melatonin production and the astrocytes and glial cells have been proven to produce melatonin. These two sources of melatonin may be responsible for its high levels in CNS. The physiological significance of the high levels of melatonin in CNS presumably is to protect neurons and glia from oxidative stress. Melatonin as a potent antioxidant has been reported to be a neuroprotector in animals and in clinical studies. It seems that long term melatonin administration which elevates CSF melatonin concentrations will retard the progression of neurodegenerative disorders, for example, Alzheimer disease.
Keywords: Melatonin, pineal gland, CNS, CSF, oxidative stress, neurodegenerative disease
Current Neuropharmacology
Title: Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Volume: 8 Issue: 3
Author(s): Dun-Xian Tan, Lucien C. Manchester, Emilio Sanchez-Barcelo, Maria D. Mediavilla and Russel J. Reiter
Affiliation:
Keywords: Melatonin, pineal gland, CNS, CSF, oxidative stress, neurodegenerative disease
Abstract: Levels of melatonin in mammalian circulation are well documented; however, its levels in tissues and other body fluids are yet only poorly established. It is obvious that melatonin concentrations in cerebrospinal fluid (CSF) of mammals including humans are substantially higher than those in the peripheral circulation. Evidence indicates that melatonin produced in pineal gland is directly released into third ventricle via the pineal recess. In addition, brain tissue is equipped with the synthetic machinery for melatonin production and the astrocytes and glial cells have been proven to produce melatonin. These two sources of melatonin may be responsible for its high levels in CNS. The physiological significance of the high levels of melatonin in CNS presumably is to protect neurons and glia from oxidative stress. Melatonin as a potent antioxidant has been reported to be a neuroprotector in animals and in clinical studies. It seems that long term melatonin administration which elevates CSF melatonin concentrations will retard the progression of neurodegenerative disorders, for example, Alzheimer disease.
Export Options
About this article
Cite this article as:
Tan Dun-Xian, C. Manchester Lucien, Sanchez-Barcelo Emilio, D. Mediavilla Maria and J. Reiter Russel, Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System, Current Neuropharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157015910792246182
DOI https://dx.doi.org/10.2174/157015910792246182 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Meet Our Editorial Board Member
Current Alzheimer Research Microglial Senescence
CNS & Neurological Disorders - Drug Targets Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Combined Fine-Motor Tests and Self-Assessments for Remote Detection of Motor Fluctuations
Recent Patents on Biomedical Engineering (Discontinued) Full Kinetics and a Mechanistic Investigation of the Synthesis of Tetrahydrobenzo[ b]pyrans in the Presence of Sodium Acetate as a Catalyst by a One-pot Three-component Reaction
Letters in Organic Chemistry Selecting Good ‘Drug-Like’ Properties to Optimize Small Molecule Blood-Brain Barrier Penetration
Current Medicinal Chemistry A Review for Lithium: Pharmacokinetics, Drug Design, and Toxicity
CNS & Neurological Disorders - Drug Targets Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Natural Products based P-glycoprotein Activators for Improved β-amyloid Clearance in Alzheimer’s Disease: An in silico Approach
Central Nervous System Agents in Medicinal Chemistry Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research MicroRNAs: Newcomers into the ALS Picture
CNS & Neurological Disorders - Drug Targets Targeting Neurotrophin Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Intrinsically Disordered Domains, Amyloids and Protein Liquid Phases: Evolving Concepts and Open Questions
Protein & Peptide Letters Blood-based Amyloid and Tau Biomarker Tests For Alzheimer’s Disease
Neuroscience and Biomedical Engineering (Discontinued) The Role of Components of the Lymphoreticular System in Transmissible Spongiform Encephalopathy Pathogenesis and Neuroinvasion
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hybrid Molecules Development: A Versatile Landscape for the Control of Antifungal Drug Resistance: A Review
Mini-Reviews in Medicinal Chemistry The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology